Table 2. Prevalence of medical comorbidities not included in the VACS index across total cohort and as per predicted high and low risk 5 year mortality as estimated by VACS index.
|
|
Predicted risk of mortality |
|||||
|---|---|---|---|---|---|---|
|
|
Overall | Low risk | High risk | Statistic | ||
| Variable |
N(%) | N (%) | N (%) | p-value | ||
| Participants |
314 (100) | 261 (83.1) | 53 (16.9) | |||
| Metabolic diseases |
120 (38.2) | 95 (79) | 25 (21) | p=0.14 | ||
| Dyslipidemia | 92 (29.3) | 76 (83) | 16 (17) | p=0.88 | ||
| Diabetes mellitus | 22 (7.0) | 15 (68) | 7 (32) | p=0.05 | ||
| Hypogonadism | 9 (2.9) | 5 (56) | 4 (44) | p=0.03 | ||
| Cardiovascular diseases | 75 (23.9) | 52 (57) | 23 (43) | p<0.001 | ||
| Hypertension | 55 (17.5) | 36 (69) | 19 (34) | p<0.001 | ||
| Myocardial infarction | 10 (3.2) | 7 (70) | 3 (30) | p=0.26 | ||
| Peripheral vascular disease | 8 (2.5) | 4 (50) | 4 (50) | p=0.01 | ||
| Stroke | 3 (0.9) | 2 (67) | 1 (33) | p=0.45 | ||
| Cancer | 39 (12.4) | 29 (74) | 10 (26) | p=0.12 | ||
| Renal diseases | 104 (33.1) | 77 (74) | 27 (26) | p=0.01 | ||
| Proteinuria | 95 (30.2) | 72 (76) | 23 (24) | p=0.07 | ||
| Hepatitis B | ||||||
| Non-responder/never infected | 58 (18.5) | 47 (81) | 11 (19) | |||
| Vaccine responder | 134 (42.7) | 123 (92) | 11 (8) | |||
| Cleared/Past infection | 100 (31.8) | 75 (75) | 25 (25) | |||
| Currently infected | 22 (7.0) | 16 (73) | 6 (27) | p=0.003 | ||